EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

Zhen Li, Binglei Zhang, Xinxin Fan, Ruirui Gui, Fengkuan Yu, Juan Wang, Yanli Zhang, Keshu Zhou, Yanyan Liu, Yufu Li, Jing Ding, Yongping Song und 1 weitere

Frontiers in Oncology · 20.07.2023 · 13

DOI: 10.3389/fonc.2023.1193237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.07.2023. Verfasst von Zhen Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hematopoietic stem cell transplantation (HSCT) is an important treatment for T-cell lymphoblastic lymphoma/leukemia (T-LBL). To compare the efficacy and influencing factors of autologous hematopoietic stem cell transplantation (auto-HSCT) with those of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from different donors for the treatment of T-cell lymphoblastic lymphoma/leukemia (T-LBL) and provide a basis for selection of appropriate transplant methods and donors.

Methods

To provide evidence of appropriate transplant methods for these patients, we retrospectively summarized the clinical characteristics of 75 T-LBL patients receiving HSCT at Henan Cancer Hospital between March 2012 and October 2021. Overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and related factors affecting efficacy were analyzed.

Results

The 3-year CIR (39.9% vs 31.1%, P=0.745), 3-year PFS (60.1% vs 49.6%, P=0.434), and 3-year OS (62.8% vs 53.0%, P=0.450) were not significantly different between the auto-HSCT and allo-HSCT groups. However, the 3-year NRM was significantly higher in the allo-HSCT group (0% vs 27.2%, P=0.033). Multivariate analysis showed that the first complete remission (CR1) after HSCT was an independent influencing factor of higher OS (HR=2.498, P=0.029) and PFS (HR=2.576, P=0.016). The absence of mediastinal invasion in patients receiving HSCT was an independent influencing factor of better PFS (HR=2.977, P=0.029) and lower CIR (HR=4.040, P=0.027). With respect to the impact of donor source, the NRM in the unrelated donor (URD) and haploid donor (HPD) groups was significantly higher than that in the auto-HSCT group (P=0.021 and P=0.003, respectively), while there was no significant difference between matched sibling donors (MSD) and auto-HSCT. Compared with the MSD-HSCT group, the auto-HSCT group showed an increasing trend in 3-year CIR (39.9 ± 11.1% vs 32.6 ± 11.2%, P=0.697) and a lower trend in 3-year OS (62.8 ± 11.4% vs 64.4 ± 12.2%, P=0.929).

Conclusions

HSCT is an effective consolidation treatment option for patients with T-LBL without mediastinal invasion and with CR1 before transplantation. For CR1 patients, auto-HSCT and MSD-HSCT are effective modalities for improving survival. In non-CR1 patients without an MSD, matched unrelated donors and haploidentical donor transplantations are the best treatment options to reduce relapse and improve prognosis.

Schlagwörter

Stichwörter der Autor:innen

T-cellallo-HSCTauto-HSCThematopoietic stem cell transplantationlymphoblastic lymphoma

Autor:innen und Institutionen

  • Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China.
  • Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Zitieren

APA

Li, Z., Zhang, B., Fan, X., Gui, R., Yu, F., Wang, J., Zhang, Y., Zhou, K., Liu, Y., Li, Y., Ding, J., Song, Y., & Zhou, J. (2023). Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1193237

Vancouver

Li Z, Zhang B, Fan X, Gui R, Yu F, Wang J, et al. Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1193237

BibTeX
@article{Li2023,
  author = {Li, Zhen and Zhang, Binglei and Fan, Xinxin and Gui, Ruirui and Yu, Fengkuan and Wang, Juan and Zhang, Yanli and Zhou, Keshu and Liu, Yanyan and Li, Yufu and Ding, Jing and Song, Yongping and Zhou, Jian},
  title = {Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1193237}
}
Kostenlos starten →